NewAmsterdam Pharma (NAMS) Net Cash Flow (2023 - 2026)

NewAmsterdam Pharma has disclosed Net Cash Flow across 4 years of filings, most recently posting -$31.0 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$31.0 million, down 14.59% year-over-year; the trailing twelve-month figure through Mar 2026 was -$297.1 million (down 210.95% YoY), and the FY2025 annual result was -$293.2 million, down 166.92% from the prior year.
• Net Cash Flow came in at -$31.0 million for Q1 2026 at NewAmsterdam Pharma, up from -$48.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $357.0 million in Q4 2024 to a low of -$193.4 million in Q2 2025.
• The 4-year median for Net Cash Flow is -$30.3 million (2023), against an average of $376166.7.
• Across the five-year window, Net Cash Flow jumped 1179.15% in 2024 and plunged 290.43% in 2025, its largest moves.
• NewAmsterdam Pharma's Net Cash Flow stood at -$33.1 million in 2023, then surged by 1179.15% to $357.0 million in 2024, then slumped by 113.54% to -$48.3 million in 2025, then jumped by 35.76% to -$31.0 million in 2026.
• The last three Net Cash Flow figures came in at -$31.0 million (Q1 2026), -$48.3 million (Q4 2025), and -$24.4 million (Q3 2025), per Business Quant data.